PBMs, FTC and IRA: Experts Tackle Pharma’s Tough Acronyms At BioFuture

Some of the industry’s biggest challenges – and potential solutions to those problems – were hot topics at the BioFuture conference in New York.

(Shutterstock)
Key Takeaways
  • A BioFuture panel made up of pharmaceutical executives, a Democratic lawmaker and a health economist debated some of complicated issues industry is facing.
  • Congressman Jake Auchincloss (D-Mass) said he is sympathetic to industry’s lobbying efforts to change parts of the IRA and seek PBM reform.
  • Industry representatives said pharma also needs to take responsibility for high drug prices.

New policies on drug pricing implemented by the US government under the Inflation Reduction Act (IRA), the Federal Trade Commission (FTC)’s actions on M&A, and the thorny role of pharmacy...

An expert panel made up of pharmaceutical executives, a Democratic lawmaker and a health economist debated some of the complicated issues industry is navigating in the US – and even...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Drug Pricing

HHS Intensifies Pressure On Pharma With MFN Pricing Benchmark

 

The Trump administration released more details on “most favored nation” price targets drug companies are expected to apply to US drug prices.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By 

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By 

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

 

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.

More from Business

End Is Nigh For 4SC After EMA’s No For Kinselby

 
• By 

The German biotech has discontinued the oral HDAC inhibitor for cutaneous T-cell lymphoma.

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By 

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

Pfizer Scoops 3SBio’s PD-1/VEGF Bispecific In ADC Combo Push

 

Pfizer is doubling down on partnerships for combination therapies involving its antibody-drug conjugates through a new alliance with China's 3SBio’s for a bispecific antibody, potentially worth up to $6bn.